SVB Wealth’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

SVB Wealth’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-3,883	Closed	-$125K	–	513
2016 Q4	$125K	Sell	3,883 -2,288	-37%	-$97.6K	0.01%	474
2016 Q3	$308K	Hold	6,171	–	–	0.01%	433
2016 Q2	$262K	Hold	6,171	–	–	0.01%	444
2016 Q1	$406K	Hold	6,171	–	–	0.02%	388
2015 Q4	$384K	Sell	6,171 -2,518	-29%	-$177K	0.02%	420
2015 Q3	$582K	Hold	8,689	–	–	0.02%	385
2015 Q2	$845K	Hold	8,689	–	–	0.03%	342
2015 Q1	$812K	Hold	8,689	–	–	0.03%	338
2014 Q4	$773K	Buy	+8,689	New	+$633K	0.03%	338

Other funds holding MACK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

SVB Wealth's MACK Position: Q1 2017 in Review

SVB Wealth sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q1 2017, closing a stake of 3,883 shares — an estimated $125K sold.

SVB Wealth first reported a position in MACK in Q4 2014 and held it in 9 quarters. The position peaked at $845K in Q2 2015. 116 funds tracked by Wall St. Rank hold MACK as of Q1 2017.

SVB Wealth reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
SVB Wealth sold 3,883 Merrimack Pharmaceuticals, Inc. shares in Q1 2017, an estimated $125K.
SVB Wealth first reported a position in Merrimack Pharmaceuticals, Inc. in Q4 2014 and held it in 9 quarters.
SVB Wealth's Merrimack Pharmaceuticals, Inc. position peaked at $845K in Q2 2015.
116 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q1 2017.

Based on SVB Wealth's 13F filing for Q1 2017, filed 11 May 2017.